Filing Flows › Biomerica (BMRA) › Q3 FY25
Biomerica (BMRA) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Apr 14, 2025
Biomerica (BMRA) reported revenue of $1.1M for the third quarter fiscal 2025 (Q3 FY25), +10% from a year earlier and -32% from the quarter before. Operating margin was -108.1%, net loss $1.2M (103.9% of revenue).
Biomerica, Q3 FY25: revenue $1.1M (+10% year over year), operating margin -108.1%, net loss $1.2M, operating cash flow −$1.0M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | -32% | +10% |
| Operating profit | −$1.2M | — | — |
| Net earnings | −$1.2M | — | — |
| Operating cash flow | −$1.0M | — | — |
What changed
Revenue was $1.1M in Q3 FY25, up 10% year over year and down 32% from the previous quarter. Clinical Lab was the largest line at 56% of revenue. Clinical Lab added $223K year over year (up 55%), 219% of the total change. Over-the-counter declined 48%.
Gross margin was 1.7%. Operating costs exceeded revenue by $1.2M, an operating margin of -108.1%. The quarter ended with a net loss of $1.2M, wider than the previous quarter's $0.9M loss.
Operating cash flow was −$1.0M. Non-cash charges added back $21K of depreciation and amortization and $120K of share-based compensation.
Questions
What was Biomerica's revenue in the third quarter fiscal 2025?
Biomerica (BMRA) reported revenue of $1.1M for the third quarter fiscal 2025 (Q3 FY25), +10% from a year earlier and -32% from the quarter before.
Was Biomerica profitable in the third quarter fiscal 2025?
Operating loss was $1.2M (-108.1% of revenue) and net loss $1.2M.
Source: Biomerica 10-Q on SEC EDGAR.